ONVO - Organovo Holdings Inc Stock Price, Fair Value and News

1.05USD+0.06 (+6.06%)Delayed as of 15 May 2024, 12:03 pm ET

Market Summary

USD1.05+0.06

Delayedas of 15 May 2024, 12:03 pm

6.06%

ONVO Stock Price

View Fullscreen

ONVO RSI Chart

ONVO Valuation

Market Cap

9.9M

Price/Earnings (Trailing)

-0.52

Price/Sales (Trailing)

41.07

Price/Free Cashflow

-0.59

ONVO Price/Sales (Trailing)

ONVO Profitability

Operating Margin

-325.62%

Return on Equity

-308.72%

Return on Assets

-214.9%

Free Cashflow Yield

-170.22%

ONVO Fundamentals

ONVO Revenue

Revenue (TTM)

242.0K

Rev. Growth (Yr)

-96.18%

Rev. Growth (Qtr)

-100%

ONVO Earnings

Earnings (TTM)

-19.1M

Earnings Growth (Yr)

-10.42%

Earnings Growth (Qtr)

9.76%

Breaking Down ONVO Revenue

52 Week Range

1.001.96

(Low)(High)

Last 7 days

8.8%

Last 30 days

-2.0%

Last 90 days

-6.6%

Trailing 12 Months

-46.5%

How does ONVO drawdown profile look like?

ONVO Financial Health

Current Ratio

3.67

ONVO Investor Care

Shares Dilution (1Y)

15.21%

Diluted EPS (TTM)

-2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	370.0K	445.0K	368.0K	242.0K
2022	1.8M	0	1.1M	746.7K
2020	2.2M	0	0	0
2019	3.1M	3.1M	3.4M	2.9M
2018	4.6M	4.3M	3.9M	3.5M
2017	4.2M	4.3M	4.3M	4.3M
2016	1.5M	2.1M	3.1M	4.0M
2015	571.0K	778.0K	1.0M	1.2M
2014	379.0K	372.0K	399.0K	419.0K
2013	1.3M	1.1M	693.0K	479.0K
2012	564.9K	650.6K	887.6K	1.2M
2011	513.3K	423.6K	631.7K	645.7K
2010	0	0	0	603.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Organovo Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 17, 2023	joshi vaidehi	acquired	-	-	19,607	-
Nov 17, 2023	gobel david	acquired	-	-	19,607	-
Nov 17, 2023	milhous alison tjosvold	acquired	-	-	19,607	-
Nov 17, 2023	cohen douglas jay	acquired	-	-	19,607	-
Nov 17, 2023	murphy keith	acquired	-	-	19,607	executive chairman
Nov 17, 2023	stern adam k	acquired	-	-	19,607	-
Nov 15, 2023	gobel david	sold	-31,749	1.6193	-19,607	-
Nov 10, 2022	gobel david	acquired	-	-	19,607	-
Nov 10, 2022	stern adam k	acquired	-	-	19,607	-
Nov 10, 2022	murphy keith	acquired	-	-	19,607	executive chairman

Which funds bought or sold ONVO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	FMR LLC	new	-	52.00	52.00	-%
May 13, 2024	XTX Topco Ltd	new	-	23,307	23,307	-%
May 13, 2024	UBS Group AG	added	479	12,669	15,560	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	1.02	-5,154	77,177	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-3.65	-12,000	101,000	-%
May 10, 2024	VANGUARD GROUP INC	unchanged	-	-28,289	364,220	-%
May 10, 2024	JPMORGAN CHASE & CO	added	16.67	5.00	65.00	-%
May 10, 2024	BlackRock Inc.	reduced	-3.6	-17,274	146,474	-%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-7.42	-330	2,018	-%
May 10, 2024	McIlrath & Eck, LLC	sold off	-100	-39.00	-	-%

Are Funds Buying or Selling ONVO?

Are funds buying ONVO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ONVO

No. of Funds

Unveiling Organovo Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 12, 2024	nikko asset management americas, inc.	0%	0	SC 13G/A
Feb 05, 2024	sumitomo mitsui trust holdings, inc.	0.00%	0	SC 13G/A
Feb 10, 2023	nikko asset management americas, inc.	5.21%	454,752	SC 13G/A
Feb 03, 2023	sumitomo mitsui trust holdings, inc.	5.21%	454,752	SC 13G/A
Feb 14, 2022	nikko asset management americas, inc.	5.50%	478,570	SC 13G/A
Feb 04, 2022	sumitomo mitsui trust holdings, inc.	5.49%	478,570	SC 13G/A
Mar 10, 2021	ark investment management llc	9.48%	674,454	SC 13G/A
Feb 16, 2021	ark investment management llc	20.86%	1,404,620	SC 13G/A
Feb 11, 2021	nikko asset management americas, inc.	7.11%	478,570	SC 13G/A
Feb 11, 2021	renaissance technologies llc	5.36%	381,353	SC 13G/A

Recent SEC filings of Organovo Holdings Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	424B4	Prospectus Filed
May 13, 2024	8-K	Current Report
May 10, 2024	424B4	Prospectus Filed
May 08, 2024	EFFECT	EFFECT
May 01, 2024	8-K	Current Report
Apr 30, 2024	S-1/A	Initial Public Offering
Apr 23, 2024	8-K	Current Report
Apr 12, 2024	S-1	Initial Public Offering
Feb 12, 2024	SC 13G/A	Major Ownership Report
Feb 08, 2024	424B5	Prospectus Filed

Peers (Alternatives to Organovo Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	22.08%	-1.47%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.34%	-28.23%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-13.63%	-16.32%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	5.96%	-13.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	8.09%	95.42%	-9.91	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-20.37%	-53.19%	-11.98	9.54	394.93%	39.61%
AXSM	3.7B	251.0M	11.93%	-0.48%	-12.39	14.63	73.58%	-86.73%
ARWR	2.8B	240.7M	-7.33%	-42.62%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.36%	-32.87%	-1.4K	3.02	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	8.34%	25.49%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	214.95%	66.21%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	4.53%	306.67%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.99%	24.13%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-6.93%	99.64%	-0.7	7.61	-13.45%	69.54%

Organovo Holdings Inc News

Latest updates

Organovo Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q1	2022Q1	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1
Revenue	-	5.00	-	75.00	162	131	77.00	51.00	26.00	-	298	1,230	668	680	779	943	689	1,105	1,153	1,355	990	812
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	283	192	254	301	183
Costs and Expenses	-10.4%	3,685	4,115	4,270	7,941	3,490	3,431	-	-	2,893	5,532	8,057	7,189	7,842	7,305	6,952	8,266	8,688	9,062	10,934	-	-
Operating Expenses	-	-	-	-	-	3,490	3,431	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-19.0%	2,251	2,780	2,604	2,492	2,305	2,200	2,278	-	3,022	5,374	6,348	3,315	3,337	3,387	3,640	4,767	4,431	-	-	-	-
R&D Expenses	7.4%	1,434	1,335	1,666	5,449	1,185	1,231	1,135	-	-129	145	1,445	3,823	4,404	3,782	3,187	3,379	3,974	-	-	-	-
EBITDA Margin	-	-	-	-	-	-	-	-	-	0.46*	0.41*	0.20*	0.25*	0.28*	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	-	-	-	-	-
Income Taxes	-	-	-	2.00	-	-	-	-	-	-	-	2.00	-	-	-	-	3.00	2.00	-	-	-	-
EBT Margin	-	-	-	-	-	-	-	-	-	-0.06*	-0.05*	-0.04*	-0.04*	-0.04*	-	-	-	-	-	-	-	-
Net Income	9.8%	-3,604	-3,994	-4,028	-7,459	-3,264	-3,321	-1,911	-	-2,723	-3,370	-6,294	-6,323	-6,983	-6,399	-5,837	-7,416	-7,449	-	-	-	-
Net Income Margin	-54.8%	-78.86*	-50.94*	-40.61*	-46.65*	-17.95*	-12.78*	-7.63*	-5.53*	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-8.3%	-3,482	-3,216	-5,315	-4,870	-3,110	-2,336	-1,594	-3,489	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-20.4%	8,881	11,161	14,756	20,313	25,079	27,910	30,546	33,296	35,095	35,881	38,294	39,917	21,581	20,644	25,621	28,441	31,312	37,771	43,451	40,623	39,685
Current Assets	-24.8%	6,241	8,296	11,695	17,048	21,614	24,357	26,909	29,533	31,171	34,303	36,658	38,398	20,099	19,485	25,501	28,318	31,106	32,714	37,356	38,574	37,471
Cash Equivalents	-30.5%	5,295	7,617	10,754	15,301	20,196	13,265	15,568	28,675	30,269	33,791	36,008	37,364	18,836	17,656	24,787	27,356	30,467	30,350	35,487	36,477	35,224
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	351	506	490	1,049
Net PPE	-8.5%	739	808	850	902	742	758	690	662	652	552	554	381	289	22.00	-	-	-	758	1,594	1,832	1,946
Liabilities	-0.2%	2,699	2,705	2,980	4,984	2,790	2,904	2,892	3,087	3,802	2,775	1,748	721	-	-	-	1,810	2,358	6,698	7,312	4,325	4,010
Current Liabilities	6.3%	1,700	1,600	1,770	3,671	1,376	1,389	1,282	1,383	2,006	1,675	964	721	829	658	835	1,810	2,358	3,122	3,538	3,737	3,410
Shareholder's Equity	-26.9%	6,182	8,456	11,776	15,329	22,289	25,006	27,654	30,209	31,293	34,206	37,330	39,196	20,752	19,986	24,786	26,631	28,954	31,073	36,139	36,298	35,675
Retained Earnings	-1.1%	-336,600	-333,000	-329,026	-324,998	-317,539	-314,275	-311,000	-307,739	-305,828	-302,328	-298,800	-296,291	-293,695	-291,184	-282,234	-279,465	-276,742	-273,372	-267,078	-260,755	-253,772
Additional Paid-In Capital	0.4%	342,796	341,467	340,792	340,317	339,817	339,273	338,600	337,940	337,113	336,526	336,145	335,479	314,441	311,164	306,889	306,089	305,566	304,315	303,087	296,929	289,329
Shares Outstanding	12.8%	9,839	8,719	8,718	8,717	8,712	8,712	8,711	8,711	8,703	8,705	8,697	8,670	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	16,721	-	-	-	58,025	-	-	-	41,853	-	-	-	29,234	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-8.8%	-3,482	-3,200	-5,300	-4,733	-3,044	-2,217	-2,414	-1,541	-3,356	-2,143	-1,413	-2,114	-1,491	-7,148	-2,570	-3,209	-583	-5,155	-5,935	-5,077	-3,952
Share Based Compensation	-76.7%	157	675	475	500	544	673	660	827	588	426	415	287	206	4,138	925	400	1,252	1,236	1,220	1,282	1,358
Cashflow From Investing	125.0%	27.00	12.00	764	-162	9,975	-86.00	-10,693	-53.00	-133	-29.00	-194	-111	-289	5.00	2.00	19.00	701	26.00	1.00	-42.00	-25.00
Cashflow From Financing	-	1,173	-	-	-	-	-	-	-	-1.00	-45.00	251	20,753	3,071	12.00	-1.00	-	-1.00	-8.00	4,944	6,324	1,846
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ONVO Income Statement

2023-12-31

Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenues
Total Revenues	$ 5	$ 131	$ 80	$ 208
Revenue From Contract With Customer Product And Service [Extensible List]	us-gaap:RoyaltyMember	us-gaap:RoyaltyMember	us-gaap:RoyaltyMember	us-gaap:RoyaltyMember
Research and development expenses	$ 1,434	$ 1,185	$ 4,435	$ 3,436
Selling, general and administrative expenses	2,251	2,305	7,635	6,724
Total costs and expenses	3,685	3,490	12,070	10,160
Loss from Operations	(3,680)	(3,359)	(11,990)	(9,952)
Other Income (Expense)
(Loss) gain on investment in equity securities	0	(48)	12	(123)
Interest income	76	143	354	277
Total Other Income	76	95	366	154
Income Tax Expense	0	0	(2)	(2)
Net Loss	(3,604)	(3,264)	(11,626)	(9,800)
Other Comprehensive Loss:
Unrealized gain (loss) on available-for-sale debt securities	0	3	(1)	3
Comprehensive loss	$ (3,604)	$ (3,261)	$ (11,627)	$ (9,797)
Net loss per common share basic	$ (0.40)	$ (0.37)	$ (1.31)	$ (1.13)
Net loss per common share diluted	$ (0.40)	$ (0.37)	$ (1.31)	$ (1.13)
Weighted average shares used in computing net loss per common share basic	9,115,455	8,713,617	8,850,881	8,712,294
Weighted average shares used in computing net loss per common share diluted	9,115,455	8,713,617	8,850,881	8,712,294

ONVO Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Current Assets
Cash and cash equivalents	$ 5,295	$ 15,301
Accounts receivable	33	152
Investment in equity securities	0	706
Prepaid expenses and other current assets	913	889
Total current assets	6,241	17,048
Fixed assets, net	739	902
Restricted cash	143	143
Operating lease right-of-use assets	1,403	1,705
Prepaid expenses and other assets, net	355	515
Total assets	8,881	20,313
Current Liabilities
Accounts payable	471	331
Accrued expenses	727	2,848
Operating lease liability, current portion	502	492
Total current liabilities	1,700	3,671
Operating lease liability, net of current portion	999	1,313
Total liabilities	2,699	4,984
Commitments and Contingencies (Note 7)
Stockholders’ Equity
Common stock, $0.001 par value; 200,000,000 shares authorized, 9,838,755 and 8,716,906 shares issued and outstanding at December 31, 2023 and March 31, 2023, respectively	10	9
Additional paid-in capital	342,796	340,317
Accumulated deficit	(336,624)	(324,998)
Accumulated other comprehensive income	1	2
Treasury stock, 46 shares at cost	(1)	(1)
Total stockholders’ equity	6,182	15,329
Total Liabilities and Stockholders’ Equity	$ 8,881	$ 20,313

About Organovo Holdings Inc

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

WEBSITE	organovo.com
INDUSTRY	Biotechnology
EMPLOYEES	23

Organovo Holdings Inc Frequently Asked Questions

What is the ticker symbol for Organovo Holdings Inc? What does ONVO stand for in stocks?

ONVO is the stock ticker symbol of Organovo Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Organovo Holdings Inc (ONVO)?

As of Tue May 14 2024, market cap of Organovo Holdings Inc is 9.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ONVO stock?

You can check ONVO's fair value in chart for subscribers.

What is the fair value of ONVO stock?

You can check ONVO's fair value in chart for subscribers. The fair value of Organovo Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Organovo Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ONVO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Organovo Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether ONVO is over valued or under valued. Whether Organovo Holdings Inc is cheap or expensive depends on the assumptions which impact Organovo Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ONVO.

What is Organovo Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, ONVO's PE ratio (Price to Earnings) is -0.52 and Price to Sales (PS) ratio is 41.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ONVO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Organovo Holdings Inc's stock?

In the past 10 years, Organovo Holdings Inc has provided -0.385 (multiply by 100 for percentage) rate of return.